ANI Pharmaceuticals will acquire Alimera Sciences under the terms of a definitive agreement, according to a press release.
With the acquisition, ANI aims to strengthen its rare disease business as the largest driver of its future growth through the addition of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) for the treatment of diabetic macular edema in the United States, Europe and the Middle East, as well as noninfectious uveitis affecting the posterior segment of the eye in Europe and the Middle East, and Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) for the